Drug Firms Model Ensuring Import Safety; China's Inconsistencies Worry FDA
This article was originally published in PharmAsia News
Firms using Chinese imports to make dietary supplements and other products can look to drug firms for lessons on ensuring the safety of raw materials from China, where adherence to food and drug production regulations remains inconsistent, current and former FDA executives tell a Senate panel
You may also be interested in...
A month after saying levels of diethylene glycol found in toothpaste imported from China do not cause health problems, China has banned firms in the country from using DEG as a toothpaste ingredient, citing bans by the U.S. and other countries on sales of toothpaste products containing the chemical
House Energy and Commerce leaders say FDA's plan to close several labs - including its only facility testing for radiological contaminants - is a threat to national security, while an FDA district chief says problems are likely to hinder the agency's work early in the planned reorganization
FDA is touting an agreement with European authorities to assess food safety risks as crucial to public health protection. Meanwhile, key Democrats on Capitol Hill are asking federal agencies to "make it a top priority to develop a comprehensive, legally binding" memorandum of understanding on food safety with China